| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
AstraZeneca positive clinical data for Forxiga approved in China; gastric cancer drug gets priority review in US
StockMarketWire.com
|
Pharma giant AstraZeneca said Chinese health authorities had updated the label for Forxiga to include data from a clinical trial showing the drug 'significantly' reduced heart failure or death in type-2 diabetes patients.
Data from the Declare-Timi 58 phase 3 trial had showed Forxiga achieved a 'statistically significant reduction in the composite endpoint of hospitalisation for heart failure or cardiovascular death, versus placebo, in adults with type-2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors,' the company said.
In a separate announcement, the company said its gastric cancer drug candidate had received supplemental biologics license application and has also been granted priority review in the US.
Story provided by StockMarketWire.com
|
|
|
|
|
|
